The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Self-citationp53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
Debbas, M., & White, E. (1993) · Genes & Development · doi:10.1101/gad.7.4.546 · Cited by 871
The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.
Scheffner, M., Münger, K., Byrne, J. C., & Howley, P. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5523 · Cited by 849
Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of the Head and Neck
Brennan, J. A., Mao, L., Hruban, R. H., Boyle, J. O., Eby, Y. J., Koch, W. M., Goodman, S. N., & Sidransky, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502163320704 · Cited by 749
Dvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
Zinkernagel, R. M. (1996) · Science · doi:10.1126/science.271.5246.173 · Cited by 651
Cited by
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
A Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Forastiere, A., Koch, W., Trotti, A., & Sidransky, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmra001375 · Cited by 1,250
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Self-citationWang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Roulston, A., Marcellus, R. C., & Branton, P. E. (1999) · Annual Review of Microbiology · doi:10.1146/annurev.micro.53.1.577 · Cited by 749
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Gibbs, J. B. (2000) · Science · doi:10.1126/science.287.5460.1969 · Cited by 606
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Self-citationAdenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Self-citationUnderstanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Cancer immunotherapies: advances and bottlenecks
Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Self-citationProliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Self-citationViral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases
Walther, W., & Stein, U. (2000) · Drugs · doi:10.2165/00003495-200060020-00002 · Cited by 442
Replicative adenoviruses for cancer therapy
Alemany, R., Balagué, C., & Curiel, D. T. (2000) · Nature Biotechnology · doi:10.1038/77283 · Cited by 421
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Self-citationFrequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors
Koontz, J. I., Soreng, A. L., Nucci, M., Kuo, F. C., Pauwels, P., van den Berghe, H., Cin, P. D., Fletcher, J. A., & Sklar, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101132598 · Cited by 390
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353
Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349
Self-citationGene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 340
Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
Self-citationMulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299
Self-citationEngineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
Oncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Self-citationRayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Oncolytic herpes simplex virus vectors for cancer virotherapy
Varghese, S., & Rabkin, S. D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700537 · Cited by 264
Loss of Geminin induces rereplication in the presence of functional p53
Melixetian, M., Ballabeni, A., Masiero, L., Gasparini, P., Zamponi, R., Bartek, J., Lukas, J., & Helin, K. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403106 · Cited by 262
p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication
Harada, J. N., & Berk, A. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5333-5344.1999 · Cited by 259
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R., & Kirn, D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258
Self-citationKi67 targeted strategies for cancer therapy
Yang, C., Zhang, J., Ding, M., Xu, K., Li, L., Mao, L., & Zheng, J. (2018) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1774-3 · Cited by 254
Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy
Thorne, S. H., Negrin, R. S., & Contag, C. H. (2006) · Science · doi:10.1126/science.1121411 · Cited by 252
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., Kishimoto, H., Endo, Y., Urata, Y., Tanaka, N., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.026 · Cited by 88
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Fujiwara, T., Kagawa, S., Kishimoto, H., Endo, Y., Hioki, M., Ikeda, Y., Sakai, R., Urata, Y., Tanaka, N., & Fujiwara, T. (2006) · International Journal of Cancer · doi:10.1002/ijc.21846 · Cited by 73
Is cancer gene therapy an empty suit?
Brenner, M. K., Gottschalk, S., Leen, A. M., & Vera, J. F. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70173-6 · Cited by 52
Metadata
- Authors
- Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H.
- Venue
- Nature Medicine
- Published
- 1997-06
- Volume
- 3
- Issue
- 6
- Pages
- 639-645
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2011206688
- Cited by
- 940
- References
- 31
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.